Figure 6

Toca-1 is highly expressed breast cancer subtypes with frequent p53 mutations and is associated with poor prognosis. (A) Representative micrographs showing the range of expression of Toca-1 and p53 in human invasive ductal carcinomas based on IHC staining. (B) Graph depicts quantification of Toca-1 levels using H-score analysis according to p53 IHC staining patterns (EP/EN, extreme positive/extreme negative; NE, non-extreme or intermediate levels) in 63 human ductal carcinomas (^*indicates a significant difference between groups based on paired Student’s t test, P <0.05). (C) Representative micrographs showing results of Toca-1 IHC staining in human breast cancer subtypes, including luminal, HER2 and TNBCs. (D) Graph depicts quantification of Toca-1 IHC staining using H-score analysis, and grouped by molecular subtypes (luminal, HER2 and TNBC; significant differences between groups based on paired Student’s t test are indicated by ^*P <0.05 or ^**P <0.01). (E) Kaplan-Meier Plotter analysis of basal breast cancer patients with high or low Toca-1 transcript levels according to relapse-free survival (n = 581; HR = 1.5, logrank P <0.01). (F) A schematic model depicting known targets of WT p53 (EGFR, Cdc42, Toca-1) that upon p53 loss or mutation, promote formation of invadopodia, invasion through ECM, and tumor metastasis. ECM, extracellular matrix; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; TNBCs, triple-negative breast cancers; Toca-1, transducer of Cdc42-mediated actin assembly.